The BioCentury Show
The BioCentury Show
BioCentury
Ep. 100 - Adam Koppel on Why Private Equity Is Moving Deeper Into Biotech and What Comes Next
36 minutes Posted Jan 9, 2026 at 3:00 am.
Introduction
PE's Evolution in Biotech
Bain's Priorities
Structuring Deals
Capital Market Conditions
Environment for Private Companies
IPO Outlook
0:00
36:45
Download MP3
Show notes
Private equity’s expanding role in biopharma as a growth equity investor reflects both the maturation of the life sciences sector and the rising need for large-scale capital, alongside PE firms’ increasing ability to conduct the technical diligence required for investments once considered too risky for their models. In conversation with The BioCentury Show's Stephen Hansen, Bain Capital’s Adam Koppel discussed the evolution of private equity's interest in biotech, Bain’s prioritization scheme...